Vnitr Lek 2021, 67(1):22-28 | DOI: 10.36290/vnl.2021.003

Patent foramen ovale from the point of view of interventional cardiology

Martin Poloczek, Petr Kala, Tomáš Ondrúš
Interní a kardiologická klinika FN Brno a LF MU, Brno

The link between patent foramen ovale (PFO) and paradoxical embolization, which may be cause of so-called "cryptogenic" ischemic stroke, has been known for more than 100 years. The catheteriziation closure of PFO as a secondary preventive treatment is performed in a greater extent since the end of the last century. The results of the first epidemiological and randomised clinical trials comparing antiagregation or anticoagulant therapy with the PFO closure did not show a clear benefit of any of these approaches. In 2017, major randomized clinical trials were published that demonstrated the benefit of PFO catheter closure compared to drug therapy alone. In this summary article we describe the diagnostic procedure of patients with PFO undergoing paradoxical embolization, indications and selections of a suitable patient for catheter closure of PFO, the procedure itself and subsequent clinical follow-up of these patients.

Keywords: catheterization closure, cryptogenic stroke, occluder, patent foramen ovale.

Published: March 2, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Poloczek M, Kala P, Ondrúš T. Patent foramen ovale from the point of view of interventional cardiology. Vnitr Lek. 2021;67(1):22-28. doi: 10.36290/vnl.2021.003.
Download citation

References

  1. Hart RG, Diener H‑C, Coutts SB et al. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol. 2014; 13(4): 429-438. Go to original source... Go to PubMed...
  2. Di Tullio M, Sacco RL, Gopal A et al. Patent foramen ovale as a risk factor for cryptogenic stroke. Ann Intern Med. 1992;117(6): 461-465. Go to original source... Go to PubMed...
  3. Furlan AJ, Reisman M, Massaro J et al. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med. 2012;366(11): 991-999. Go to original source... Go to PubMed...
  4. Meier B, Kalesan B, Mattle HP et al. Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med. 2013;368(12): 1083-1091. Go to original source... Go to PubMed...
  5. Carroll JD, Saver JL, Thaler DE et al. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med. 2013; 368(12): 1092-1100. Go to original source... Go to PubMed...
  6. Saver JL, Carroll JD, Thaler DE et al. Long‑Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke. N Engl J Med. 2017; 377(11): 1022-1032. Go to original source... Go to PubMed...
  7. Mas J‑L, Derumeaux G, Guillon B et al. Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke. N Engl J Med. 2017; 377(11): 1011-1021. Go to original source... Go to PubMed...
  8. Søndergaard L, Kasner SE, Rhodes JF et al. Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke. N Engl J Med. 2017; 377(11): 1033-1042. Go to original source... Go to PubMed...
  9. Lee PH, Song J‑K, Kim JS et al. Cryptogenic Stroke and High‑Risk Patent Foramen Ovale. J Am Coll Cardiol. 2018; 71(20): 2335-2342. Go to original source... Go to PubMed...
  10. Turc G, Calvet D, Guérin P et al. Closure, Anticoagulation, or Antiplatelet Therapy for Cryptogenic Stroke With Patent Foramen Ovale: Systematic Review of Randomized Trials, Sequential Meta‑Analysis, and New Insights From the CLOSE Study. J Am Heart Assoc Cardiovasc Cerebrovasc, DiS. J Am Heart Assoc. 2018; 7: 1-12. Go to original source... Go to PubMed...
  11. Pristipino C, Sievert H, D'Ascenzo F et al. European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism. EuroIntervention J Eur Collab Work Group Interv Cardiol Eur Soc Cardiol. 2019;14(13): 1389-402. Go to original source... Go to PubMed...
  12. Elgendy AY, Saver JL, Amin Z et al. Proposal for Updated Nomenclature and Classification of Potential Causative Mechanism in Patent Foramen Ovale‑Associated Stroke. JAMA Neurol. 2020; 77(7): 878-886. Go to original source... Go to PubMed...
  13. Silvestry FE, Cohen MS, Armsby LB et al. Guidelines for the Echocardiographic Assessment of Atrial Septal Defect and Patent Foramen Ovale: From the American Society of Echocardiography and Society for Cardiac Angiography and Interventions. J Am Soc Echocardiogr Off Publ Am Soc Echocardiogr. 2015; 28(8): 910-958. Go to original source... Go to PubMed...
  14. Le Moigne E, Timsit S, Ben Salem D et al. Patent Foramen Ovale and Ischemic Stroke in Patients With Pulmonary Embolism: A Prospective Cohort Study. Ann Intern Med. 2019; 170(11): 756-763. Go to original source... Go to PubMed...
  15. Kent DM, Saver JL, Ruthazer R et al. Risk of Paradoxical Embolism (RoPE)-Estimated Attributable Fraction Correlates With the Benefit of Patent Foramen Ovale Closure: An Analysis of 3 Trials. Stroke. 2020; 51(10): 3119-3123. Go to original source... Go to PubMed...
  16. Kent DM, Ruthazer R, Weimar C et al. An index to identify stroke‑related vs incidental patent foramen ovale in cryptogenic stroke. Neurology. 2013; 81(7): 619-625. Go to original source... Go to PubMed...
  17. Safouris A, Kargiotis O, Psychogios K et al. A Narrative and Critical Review of Randomized‑Controlled Clinical Trials on Patent Foramen Ovale Closure for Reducing the Risk of Stroke Recurrence. Front Neurol. 2020; 11: 434. Go to original source...
  18. Thijs VN, Brachmann J, Morillo CA et al. Predictors for atrial fibrillation detection after cryptogenic stroke: Results from CRYSTAL AF. Neurology. 2016; 86(3): 261-269. Go to original source... Go to PubMed...
  19. King TD, Thompson SL, Steiner C et al. Secundum atrial septal defect. Nonoperative closure during cardiac catheterization. JAMA. 1976; 235(23): 2506-2509. Go to original source... Go to PubMed...
  20. Bridges ND, Hellenbrand W, Latson et al. Transcatheter closure of patent foramen ovale after presumed paradoxical embolism. Circulation. 1992; 86(6): 1902-1908. Go to original source... Go to PubMed...
  21. Meier B. Patent foramen ovale and closure technique with the amplatzer occluder. Scientifica. 2014; 2014: 129196. Go to original source... Go to PubMed...
  22. Wahl A, Tai T, Praz F et al. Late results after percutaneous closure of patent foramen ovale for secondary prevention of paradoxical embolism using the amplatzer PFO occluder without intraprocedural echocardiography: effect of device size. JACC Cardiovasc Interv. 2009; 2(2): 116-123. Go to original source... Go to PubMed...
  23. De Rosa S, Sievert H, Sabatino J et al. Percutaneous Closure Versus Medical Treatment in Stroke Patients With Patent Foramen Ovale: A Systematic Review and Meta‑analysis. Ann Intern Med. 2018; 168(5): 343-350. Go to original source... Go to PubMed...
  24. Mechl M, Tintěra J, Žižka J et al. Kontraindikace a rizika vyšetření pomocí magnetické rezonance. Ces Radiol. 2010; 64(1): 69-75.




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.